


BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

Date: 02.02.2023

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir / Madam,

Sub: Outcome of the Board Meeting of the board held on 02.02.2023.

Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith unaudited financial result for quarter ended 31st December 2022 and board meeting concluded on 02.35 P.M.

Kindly take the same on your record and oblige.

Thanking You.

Yours Faithfully,
FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED



Director/Authorised Signatory

BIOGEN PHARMACHEM INDUSTRIES LIMITED

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended December 31, 2022

(Rs. In lacs)							
Sl No.	Particulars	Quarter Ended 31 Dec'2022	Quarter Ended 30 Sept'2022	Quarter Ended 31 Dec'2021	Nine Monts Ended 31 Dec'2022	Nine Monts Ended 31 Dec'2021	Year Ended 31 Mar 2022
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
(a)	Revenue from Operations	-	-	-	-	247.42	247.42
(b)	Other Income	32.50	205.01	2.87	83.83	(13.56)	(30.54)
	Total Income from Operations (Net)	32.50	205.01	2.87	83.83	233.86	216.88
2	Expenses						
(a)	Cost of material consumed	-	-	-	-	201.49	201.49
(b)	Purchase of stock in trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	0.48	0.48	1.32	1.97	4.10	5.42
(e)	Finance Costs	-	-	-	-	-	-
(f)	Depreciation and Amortization Expense	-	-	-	-	-	-
(g)	Other expenses	1.89	10.40	0.47	16.63	6.03	10.83
	Total Expenses	2.37	10.88	1.79	18.60	211.62	217.74
3	Profit / (Loss) from operations before exceptional items and Tax (1-2)	30.13	194.13	1.08	65.23	22.24	(0.86)
4	Exceptional Items						
5	Profit / (Loss) before Tax (3+4)	30.13	194.13	1.08	65.23	22.24	(0.86)
6	Tax Expense						



RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848 Email : rishisekhri@gmail.com

Limited Review Report

To
The Board of Directors of
Biogen Pharmachem Industries Limited
Rajkot

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Biogen Pharmachem Industries Limited** ("the Company"), for the Quarter ended on December 31, 2022 and year to date result for the period from 01 April, 2022 to 31 December, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed. or f

[Handwritten signature in blue ink]

